Full Press Release Details
CervoMed to Participate in the Emerging Growth Conference 66.
CRVO
CervoMed to Participate in the Emerging Growth Conference 66
Key Takeaway: CervoMed to Participate in the Emerging Growth Conference 66
Price reaction · baseline $9.4 (2024-01-04 close) · hit after-hours · clean, no other CRVO news in the window
day 0 close
0%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
6.8%
average across 6 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
Neflamapimod
Phase 2 · Moderate to Severe Acute Ischaemic Stroke